Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir vs Abacavir switch for HIV-associated lipoatrophy
NCT00270556Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2003
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of tenofovir disoproxil fumarate in HIV-associated lipoatrophy and dyslipidemia (2 arms), sponsored by Gilead Sciences. Primary endpoint: Change in Total Limb Fat Mass at 48 weeks. Started Jan 2003; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
HIV-associated lipoatrophydyslipidemia
Beyond the preview
Go deeper on NCT00270556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270556.